---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015149"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:03:12.241837+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Phase 3 SAPPHIRE trial meets primary endpoint; Q3 net loss $64.5M

## Summary
- Phase 3 SAPPHIRE achieved primary endpoint: apitegromab 1.8-point HFMSE improvement (p=0.0192) vs placebo.
- Plans to submit BLA and MAA for apitegromab in SMA in Q1 2025.
- Phase 2 EMBRAZE trial (apitegromab + GLP-1 for obesity) fully enrolled; data expected Q2 2025.
- Completed upsized $345M public offering; proforma cash $463.5M extends runway into Q4 2026.
- Q3 2024 net loss $64.5M ($0.66/share) vs $42.4M ($0.53/share) in Q3 2023; no revenue.

## SEC filing metadata
- accession: 0001558370-24-015149
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/0001558370-24-015149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015149
- JSON: https://secwatch.observer/filing/0001558370-24-015149.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.